Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Keulen

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Current Medical Research and Opinion|January 1, 1973
A double-blind clinical and ECG-evaluation of lidoflazine (R 7904) in the treatment of stabilized angina pectorisU W Keulen
Biotechniques|February 1, 1991
Modified protocol for DNA sequence analysis using Sequenase 2.0R Schuurman, W Keulen
Antiviral Research|June 1, 1996
Nucleotide substitution patterns can predict the requirements for drug-resistance of HIV-1 proteinsW Keulen, C Boucher, B Berkhout
International Journal of Cardiology|June 1, 1983
Control of ventricular ectopic beats with intravenous lorcainide maintained by oral dosesR Terryn, U W Keulen, W Amery
Science (New York, N.Y.)|January 10, 1997
Reverse transcriptase fidelity and HIV-1 variationW Keulen, M Nijhuis, R Schuurman, et al.
Virology|May 1, 1992
Natural HIV-1 NEF accelerates virus replication in primary human lymphocytesA de Ronde, B Klaver, W Keulen, et al.
Virology|May 5, 2001
Evolution of AZT resistance in HIV-1: the 41-70 intermediate that is not observed in vivo has a replication defectR E Jeeninga, W Keulen, C Boucher, et al.
Journal of Virology|November 9, 2000
Estimating relative fitness in viral competition experimentsA F Marée, W Keulen, C A Boucher, et al.
AIDS (London, England)|August 17, 1999
Increased polymerase fidelity of lamivudine-resistant HIV-1 variants does not limit their evolutionary potentialW Keulen, A van Wijk, R Schuurman, et al.
Journal of Virology|November 1, 1992
Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytium-inducing phenotype: analysis by single amino acid substitutionJ J De Jong, A De Ronde, W Keulen, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Current Medical Research and Opinion|January 1, 1973
A double-blind clinical and ECG-evaluation of lidoflazine (R 7904) in the treatment of stabilized angina pectorisU W Keulen
Biotechniques|February 1, 1991
Modified protocol for DNA sequence analysis using Sequenase 2.0R Schuurman, W Keulen
Antiviral Research|June 1, 1996
Nucleotide substitution patterns can predict the requirements for drug-resistance of HIV-1 proteinsW Keulen, C Boucher, B Berkhout
International Journal of Cardiology|June 1, 1983
Control of ventricular ectopic beats with intravenous lorcainide maintained by oral dosesR Terryn, U W Keulen, W Amery
Science (New York, N.Y.)|January 10, 1997
Reverse transcriptase fidelity and HIV-1 variationW Keulen, M Nijhuis, R Schuurman, et al.
Virology|May 1, 1992
Natural HIV-1 NEF accelerates virus replication in primary human lymphocytesA de Ronde, B Klaver, W Keulen, et al.
Virology|May 5, 2001
Evolution of AZT resistance in HIV-1: the 41-70 intermediate that is not observed in vivo has a replication defectR E Jeeninga, W Keulen, C Boucher, et al.
Journal of Virology|November 9, 2000
Estimating relative fitness in viral competition experimentsA F Marée, W Keulen, C A Boucher, et al.
AIDS (London, England)|August 17, 1999
Increased polymerase fidelity of lamivudine-resistant HIV-1 variants does not limit their evolutionary potentialW Keulen, A van Wijk, R Schuurman, et al.
Journal of Virology|November 1, 1992
Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytium-inducing phenotype: analysis by single amino acid substitutionJ J De Jong, A De Ronde, W Keulen, et al.
Pageof 2